Medical equipment industry
The first patient implant for a study evaluating an implanted device to treat chronic migraines was conducted by Medtronic, Inc. in a 47-year-old female who has suffered from chronic headaches for eight years. The study, called Occipital Nerve Stimulation for the Treatment of Intractable Migraine (ONSTIM), involves a Medtronic Synergy
Medical equipment industry
Medtronic, a leading developer of implantable cardioverter-defibrillators (ICDs), has welcomed the decision by the US Centers for Medicare and Medicaid Services (CMS) to broaden reimbursement coverage for the life-saving devices. The CMS proposed rule would expand coverage to Medicare patients with heart failure who meet certain criteria for ICD implants.
Medical equipment industry
Boston Scientific's flagship product, the Taxus stent, has dominated the market for drug-coated stents since its introduction last spring. However, evidence is emerging that Johnson & Johnson's Cordis gives better patient results, threatening to dethrone Taxus from its market leading position. Despite strong quarterly earnings and
Medical equipment industry
Corautus Genetics, Inc., a clinical-stage biopharmaceutical company, has recently closed two financings, bringing in a total of $20 million. The funds will be used to support the company's phase IIb clinical trial, known as GENASIS, for the treatment of severe cardiovascular disease. The trial, initiated earlier this quarter,
Medical equipment industry
Medtronic has completed patient enrollment in the ENDEAVOR III clinical trial in the United States, marking a significant milestone in the company's drug-eluting stent development program. The trial aims to evaluate the safety and efficacy of the Endeavor Drug Eluting Coronary Stent versus the Cypher Sirolimus-eluting stent, with
Medical equipment industry
PDSHeart, Inc. has announced a partnership with Medtronic, Inc. to offer a monthly turnkey service plan providing automated external defibrillators (AEDs) for patients to use at home. The American Heart Association estimates that up to 450,000 Americans die each year from sudden cardiac arrest, with nearly 80% happening in
Medical equipment industry
The US Food and Drug Administration (FDA) has approved an expanded indication for Guidant Corporation's portfolio of cardiac resynchronization therapy defibrillators (CRT-D). This decision is based on results from the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial, which was sponsored solely by Guidant.
Medical equipment industry
Guidant Corp. has announced U.S. Food and Drug Administration (FDA) approval of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System, designed to reduce the risk of stroke associated with carotid artery disease. This approval marks the first time a carotid stent and embolic protection system
Medical equipment industry
Zacks.com released the names of 4 stocks that are currently members of the prestigious Brokerage Buy List portfolio, which outperformed the S&P 500 with a +28.5% gain in 2003. This portfolio includes stocks that are on the core recommended lists of at least three of the
Medical equipment industry
Medtronic, Inc., a leading medical technology company, has announced the U.S. Food and Drug Administration approval of the Sprint Fidelis family of defibrillation leads for patients at risk of sudden cardiac arrest. This breakthrough development allows for the implantation of smaller and more efficient defibrillation leads, which are crucial
Medical equipment industry
Corautus Genetics Inc. has closed two previously announced financings, with the second tranche of a $9.85 million private placement of common stock and warrants resulting in net proceeds of $4.7 million, and a $2.5 million convertible debt facility with Boston Scientific Corporation. The closing of both transactions
Medical equipment industry
Boston Scientific Corporation has announced the start of enrollment in the ATLAS clinical trial, marking a significant milestone in the development of its Taxus Liberte paclitaxel-eluting coronary stent system. The trial, which will assess the safety and efficacy of the Liberte stent system, is designed to enroll 822 patients at
